<link rel='stylesheet' href='https//fonts.googleapis.com/css?family=Roboto:400,500,700,400italic|Material+Icons'>
Open Search
PCVX
Vaxcyte
$
()


  • Vaxcyte price target raised by $44 at Mizuho, here's why

    3/12/2024 - 06:39am
  • Vaxcyte completes enrollment of Phase 2 study evaluating VAX-24

    3/4/2024 - 08:35am
  • Vaxcyte price target raised by $22 at Needham, here's why

    2/28/2024 - 09:41am
  • Vaxcyte price target raised by $22 at BTIG, here's why

    2/28/2024 - 07:23am
  • Vaxcyte reports Q 4 net loss $180.8M vs $78.1M last year

    2/27/2024 - 16:08pm
  • Vaxcyte price target raised by $12 at BofA, here's why

    2/6/2024 - 06:51am
  • Vaxcyte offering $500M in common stock at $64 per share, Bloomberg says

    1/30/2024 - 16:28pm
  • Vaxcyte announces common stock, warrants offering, no amount given

    1/30/2024 - 16:03pm
  • Vaxcyte price target raised by $7 at BTIG, here's why

    1/29/2024 - 20:45pm
  • Vaxcyte completes enrollment of Phase 1/2 study of VAX-31

    1/29/2024 - 08:37am
  • Vaxcyte appoints Whitney Jones as Chief People Officer

    1/16/2024 - 16:08pm
  • Needham ups Phathom target, adds to Conviction List as top 2024 pick

    1/5/2024 - 06:47am
  • Vaxcyte gives PCV franchise update, advances adult VAX-31 Phase 1/2 study

    1/4/2024 - 16:08pm
  • Vaxcyte price target raised by $8 at Guggenheim, here's why

    1/3/2024 - 09:16am
  • Vaxcyte price target raised by $13 at BofA, here's why

    1/2/2024 - 09:08am
dynamic_feed Breaking News